News
DHR
228.55
+1.06%
2.39
Dividend Champion, Contender, And Challenger Highlights: Week Of December 22
Seeking Alpha · 14h ago
5 High-Flying Stocks In Dan Loeb's Portfolio: Cinemark, Corpay, Amazon Lead
Benzinga · 2d ago
Danaher, Cryoport, Sartorius win Buy as Guggenheim expands bioprocessing coverage
Seeking Alpha · 3d ago
Least shorted S&P 500 stocks in November
Seeking Alpha · 4d ago
DHR Factor-Based Stock Analysis
NASDAQ · 4d ago
Hartford Global Impact Fund Q3 2024 Commentary
Seeking Alpha · 4d ago
Weekly Report: what happened at DHR last week (1209-1213)?
Weekly Report · 6d ago
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Seeking Alpha · 12/14 04:54
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga · 12/13 19:34
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
Benzinga · 12/13 18:57
Notable ETF Outflow Detected - XLV, TMO, ABT, DHR
NASDAQ · 12/13 18:37
Validea Detailed Fundamental Analysis - DHR
NASDAQ · 12/13 17:00
Danaher Price Target Maintained With a $290.00/Share by B of A Securities
Dow Jones · 12/13 14:01
Danaher Raised to Buy From Neutral by B of A Securities
Dow Jones · 12/13 14:01
B of A Securities Upgrades Danaher to Buy, Maintains Price Target to $290
Benzinga · 12/13 13:51
Danaher Buy Rating: Strategic Partnerships and Pricing Initiatives Drive Growth Potential
TipRanks · 12/13 13:15
Danaher upgraded to Buy at BofA following pullback
TipRanks · 12/13 12:55
Danaher upgraded to Buy from Neutral at BofA
TipRanks · 12/13 12:50
Thermo Fisher: The Cycle Has Already Turned Around
Seeking Alpha · 12/13 09:22
Is Agilent Technologies Stock Underperforming the S&P 500?
Barchart · 12/12 10:44
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.